Mouse study shows effect of blood pressure drug on Alzheimer’s disease
NIH-funded study finds drug stabilizes nerve cells in the brain
A drug used decades ago to treat high blood pressure has been shown to improve learning and memory in mouse models of Alzheimer’s disease, according to a new study by researchers at the National Institute on Aging (NIA), part of the National Institutes of Health. The study found that the drug, diazoxide, acted on nerve cells in the mouse brain in ways that slowed the development of the neurodegenerative disorder. The findings appear in the Nov. 15, 2010, print edition of the Journal of Alzheimer’s Disease.
Mark P. Mattson, Ph.D., chief of NIA’s Laboratory of Neurosciences in Baltimore, directed the research, in collaboration with colleagues at Konkuk University College of Veterinary Medicine, Seoul, South Korea, and the Indiana University School of Medicine, Indianapolis.
Mattson’s team found that diazoxide stabilized nerve cells in the brain and prevented a biological cascade in the mice that can result in the destruction of these cells. The drug also improved blood flow in the brain and prevented the harmful accumulation of two proteins, beta-amyloid and tau, which are hallmarks of Alzheimer’s. Widely used in the 1970s and ‘80s to treat patients with severe hypertension, diazoxide is currently used to treat hypoglycemia, or low blood sugar.
“These intriguing findings open new avenues of basic research that may increase our understanding of how modulating the electrical activity of nerve cells may slow the damage wrought by Alzheimer’s disease pathology,” said NIA Director Richard J. Hodes, M.D. “More research will be needed before we can determine whether this may be a potential therapy for Alzheimer’s.”
NIA scientists studied two groups of Alzheimer’s mice, one given diazoxide in drinking water and one given a placebo. After eight months, the diazoxide group outperformed the placebo group on a standard test of learning and memory. The brain tissue of the treated group showed fewer deposits of amyloid and tau proteins, less damage due to oxidative stress, and better blood flow—all indications that diazoxide may have suppressed some of the harmful cellular changes associated with Alzheimer’s disease.
“To better understand the complex biological mechanisms by which diazoxide may exert a positive effect on nerve cells, we then studied the effects of diazoxide on cultured nerve cells,” Mattson said.
The scientists found the drug activates and opens channels in the cell that enhance the movement of potassium, which then calms the electrical activity of nerve cells in parts of the brain involved in learning and memory. Diazoxide also lowered the excessive calcium often found in nerve cells in brains affected by Alzheimer’s. These beneficial effects were seen with a dose of diazoxide low enough to avoid a major decrease in blood pressure, Mattson noted.
The NIA leads the federal government effort conducting and supporting research on aging and the health and well being of older people. For more on health and on aging generally, go to www.nia.nih.gov. The NIA provides information on age-related cognitive change and neurodegenerative disease specifically at its Alzheimer’s Disease Education and Referral (ADEAR) Center at www.nia.nih.gov/alzheimers. To sign up for e-mail alerts about new findings or publications, please visit either website.
The NIH—The Nation’s Medical Research Agency—includes 27 institutes and centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.